HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/Ivax merger

This article was originally published in The Tan Sheet

Executive Summary

FTC continues to review the consent order signed by Teva Pharmaceutical and Ivax; however, the firms have "no reason to believe that the acceptance will not be forthcoming shortly," the two firms announce Jan. 10. The acquisition of Ivax by Teva is expected close on the third business day following the firms' announcement that FTC has accepted the order, they add. The deal previously was expected to close Jan. 12, and now is anticipated to close "later this month." The acquisition was announced in August (1"The Tan Sheet" Aug. 1, 2005, p. 11)...
Advertisement

Related Content

Teva Broadens Private Label OTC Offerings With Ivax Acquisition
Teva Broadens Private Label OTC Offerings With Ivax Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS099016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel